rofecoxib has been researched along with Allodynia in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to examine the regulation of COX-2 in the rat SNI model and to evaluate the effectiveness of the selective COX-2 inhibitor rofecoxib in preventing neuropathic allodynia and hyperalgesia." | 3.72 | Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. ( Broom, DC; Geisslinger, G; Kohno, T; Samad, TA; Tegeder, I; Woolf, CJ, 2004) |
| " No significant difference between the three dosage groups was observed." | 2.71 | Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. ( Anzenhofer, S; Chizh, B; Eichler, HG; Gustorff, B; Lehr, S; Schmetterer, L; Sycha, T, 2005) |
| " Following dosing of CFA-injected rats with rofecoxib (Vioxx) or paracetamol, there was a significant decrease in the number of ipsilateral CGRP-IR small and medium DRG neurones in rofecoxib- but not paracetamol-treated rats." | 1.34 | Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol. ( Bountra, C; Chessell, IP; Day, NC; Staton, PC; Wilson, AW, 2007) |
| " Ibuprofen, a non-selective COX inhibitor, at 5mg/kg, orally dosed three times a day for 5 days did not significantly affect the PWTs in CCI rats." | 1.34 | GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. ( Chessell, IP; Martindale, JC; Reeve, AJ; Spanswick, D; Zhao, FY, 2007) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated in 108 Wistar rats allocated to: (1-4) NaCl 0." | 1.33 | Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. ( Beaulieu, P; Guindon, J, 2006) |
| " Chronic administration of naproxen (3, 10 or 30 mg/kg), but not rofecoxib (1, 3 or 10 mg/kg), 2 h before, daily for 7 days, after nerve injury significantly attenuated and further delayed the development of hypersensitivity for 21 days following nerve injury." | 1.32 | Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats. ( Kulkarni, SK; Padi, SS, 2004) |
| "2." | 1.31 | Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002) |
| " Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs." | 1.30 | 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999) |
| "Rofecoxib is a potent inhibitor of the COX-2-dependent production of PGE(2) in human osteosarcoma cells (IC(50) = 26 +/- 10 nM) and Chinese hamster ovary cells expressing human COX-2 (IC(50) = 18 +/- 7 nM) with a 1000-fold selectivity for the inhibition of COX-2 compared with the inhibition of COX-1 activity (IC(50) > 50 microM in U937 cells and IC(50) > 15 microM in Chinese hamster ovary cells expressing human COX-1)." | 1.30 | Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. ( Boyce, S; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, J; Ford-Hutchinson, AW; Forrest, MJ; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Leger, S; Mancini, J; O'Neill, GP; Ouellet, M; Patrick, D; Percival, MD; Perrier, H; Prasit, P; Rodger, I, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 15 (88.24) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, WC | 1 |
| Brideau, C | 2 |
| Chan, CC | 2 |
| Charleson, S | 2 |
| Chauret, N | 1 |
| Claveau, D | 1 |
| Ethier, D | 2 |
| Gordon, R | 2 |
| Greig, G | 1 |
| Guay, J | 2 |
| Hughes, G | 1 |
| Jolicoeur, P | 1 |
| Leblanc, Y | 2 |
| Nicoll-Griffith, D | 1 |
| Ouimet, N | 1 |
| Riendeau, D | 1 |
| Visco, D | 1 |
| Wang, Z | 1 |
| Xu, L | 1 |
| Prasit, P | 2 |
| Caturla, F | 1 |
| Jiménez, JM | 1 |
| Godessart, N | 1 |
| Amat, M | 1 |
| Cárdenas, A | 1 |
| Soca, L | 1 |
| Beleta, J | 1 |
| Ryder, H | 1 |
| Crespo, MI | 1 |
| Amaya, F | 1 |
| Samad, TA | 2 |
| Barrett, L | 1 |
| Broom, DC | 2 |
| Woolf, CJ | 2 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Francischi, JN | 1 |
| Chaves, CT | 1 |
| Moura, AC | 1 |
| Lima, AS | 1 |
| Rocha, OA | 1 |
| Ferreira-Alves, DL | 1 |
| Bakhle, YS | 1 |
| Kohno, T | 1 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Padi, SS | 2 |
| Kulkarni, SK | 2 |
| Déciga-Campos, M | 1 |
| Díaz-Reval, MI | 1 |
| Ventura-Martínez, R | 1 |
| López-Muñoz, FJ | 1 |
| Sycha, T | 1 |
| Anzenhofer, S | 1 |
| Lehr, S | 1 |
| Schmetterer, L | 1 |
| Chizh, B | 1 |
| Eichler, HG | 1 |
| Gustorff, B | 1 |
| Guindon, J | 1 |
| Beaulieu, P | 1 |
| Dhir, A | 1 |
| Naidu, PS | 1 |
| Staton, PC | 1 |
| Wilson, AW | 1 |
| Bountra, C | 1 |
| Chessell, IP | 2 |
| Day, NC | 1 |
| Bove, SE | 1 |
| Laemont, KD | 1 |
| Brooker, RM | 1 |
| Osborn, MN | 1 |
| Sanchez, BM | 1 |
| Guzman, RE | 1 |
| Hook, KE | 1 |
| Juneau, PL | 1 |
| Connor, JR | 1 |
| Kilgore, KS | 1 |
| Dudhgaonkar, SP | 1 |
| Tandan, SK | 1 |
| Kumar, D | 1 |
| Naik, AK | 1 |
| Raviprakash, V | 1 |
| Zhao, FY | 1 |
| Spanswick, D | 1 |
| Martindale, JC | 1 |
| Reeve, AJ | 1 |
| Boyce, S | 1 |
| Cromlish, W | 1 |
| Evans, J | 1 |
| Ford-Hutchinson, AW | 1 |
| Forrest, MJ | 1 |
| Gauthier, JY | 1 |
| Gresser, M | 1 |
| Kargman, S | 1 |
| Kennedy, B | 1 |
| Leger, S | 1 |
| Mancini, J | 1 |
| O'Neill, GP | 1 |
| Ouellet, M | 1 |
| Patrick, D | 1 |
| Percival, MD | 1 |
| Perrier, H | 1 |
| Rodger, I | 1 |
| Mazario, J | 1 |
| Gaitan, G | 1 |
| Herrero, JF | 1 |
2 trials available for rofecoxib and Allodynia
| Article | Year |
|---|---|
Anti-hyperalgesic effects of nimesulide: studies in rats and humans.
Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; | 2002 |
Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model.
Topics: Adult; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dose-Respons | 2005 |
15 other studies available for rofecoxib and Allodynia
| Article | Year |
|---|---|
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce | 1999 |
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Blood Proteins; Cyclooxygenase 2; Humans; Hy | 2004 |
Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion.
Topics: Analysis of Variance; Animals; Autonomic Fibers, Preganglionic; Behavior, Animal; Biophysics; Cycloo | 2009 |
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib | 2002 |
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain.
Topics: Animals; Behavior, Animal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2004 |
Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Hyperalgesia; Injections, Intraperitoneal; Lactones; Male; Napro | 2004 |
Participation of the serotonin system in rofecoxib-induced antinociception.
Topics: Analgesics; Animals; Cyclooxygenase Inhibitors; Female; Hyperalgesia; Indoles; Injections, Intravent | 2004 |
Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain.
Topics: Animals; Arachidonic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, | 2006 |
Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice.
Topics: Adrenal Glands; Analysis of Variance; Animals; Anxiety; Ascorbic Acid; Behavior, Animal; Biomarkers; | 2006 |
Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Calcitonin Gene-Related P | 2007 |
Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia.
Topics: Amines; Analgesics; Animals; Arthralgia; Cyclohexanecarboxylic Acids; Cyclooxygenase 2 Inhibitors; D | 2006 |
Ameliorative effect of combined administration of inducible nitric oxide synthase inhibitor with cyclooxygenase-2 inhibitors in neuropathic pain in rats.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2007 |
GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
Topics: Action Potentials; Animals; Chronic Disease; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; | 2007 |
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acid; | 1999 |
Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cy | 2001 |